PAIOF (Paion AG) Change In Receivables: $-2.09 Mil (TTM As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PAIOF Paion AG PAIOF
10 GF Score
Price $0.07
View Full Analysis

What is Paion AG Change In Receivables?

Paion AG PAIOF 10 Change In Receivables is $-2.09 Mil as of Jun. 2023. GuruFocus rates PAIOF with a GF Score™ of 10/100.

Paion AG's change in receivables for the quarter that ended in Jun. 2023 was $-0.43 Mil. It means Paion AG's Accounts Receivable increased by $0.43 Mil from Dec. 2022 to Jun. 2023 .

Paion AG's change in receivables for the fiscal year that ended in Dec. 2022 was $-0.34 Mil. It means Paion AG's Accounts Receivable increased by $0.34 Mil from Dec. 2021 to Dec. 2022 .

Paion AG's Accounts Receivable for the quarter that ended in Jun. 2023 was $2.01 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Paion AG's Days Sales Outstanding for the six months ended in Jun. 2023 was 49.84.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Paion AG's liquidation value for the six months ended in Jun. 2023 was $-29.39 Mil.

Paion AG  (OTCPK:PAIOF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Paion AG's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=2.009/7.356*91
=49.84

2. In Ben Graham's calculation of liquidation value, Paion AG's accounts receivable are only considered to be worth 75% of book value:

Paion AG's liquidation value for the quarter that ended in Jun. 2023 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=5.035-38.248+0.75 * 2.009+0.5 * 4.641
=-29.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Paion AG Change In Receivables Related Terms

Paion AG Change In Receivables Historical Data

* Premium members only.

The historical data trend for Paion AG's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Paion AG Change In Receivables Chart

Paion AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.66 1.11 0.00 -1.81 -0.34

Paion AG Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.79 -1.07 1.32 -1.66 -0.43
PAIOF
10GF Score
Paion AG PAIOF
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Paion AG Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-2.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $-2.09 Mil mean?
Paion AG (PAIOF) has a Change In Receivables of $-2.09 Mil as of Jun. 2023. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Paion AG and its competitors.
Is Paion AG's Change In Receivables too high?
Paion AG's current Change In Receivables is $-2.09 Mil. Overall, Paion AG has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Paion AG's Change In Receivables compare to ZTS and NBIX?
Paion AG's Change In Receivables of $-2.09 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Drug Manufacturers company?
A good Change In Receivables depends on the Drug Manufacturers industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Paion AG and its competitors. Paion AG's current Change In Receivables is $-2.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paion AG stock overvalued right now?
Paion AG (PAIOF) has a current Change In Receivables of $-2.09 Mil. The current Change In Receivables is $-2.09 Mil. Paion AG's overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Paion AG (PAIOF), the current Change In Receivables is $-2.09 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Paion AG Business Description

Address Heussstrasse 25, Aachen, DEU, 52078
Paion AG is a holding company engaged in providing various services to the subsidiaries. The group is focused on developing and commercializing medical innovations for procedural sedation, anesthesia, and critical care services. The key product of the company is remimazolam, which is an ultra-short-acting intravenous benzodiazepine sedative. In the human body, remimazolam is rapidly metabolized to an inactive metabolite by tissue esterases and not metabolized by cytochrome-dependent hepatic pathways. The organization is based in Germany.
10GF Score

Get the complete analysis for PAIOF

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.07
Price